摘要 |
An oral controlled release composition, including a valproate compound, suitable for once-a-day administration characterized in that when said composition is ingested orally, said composition produces a valproate Cmax that is statistically significantly lower than the valproate Cmax produced by a delayed release divalproex sodium tablet, when each is determined at steady state in a fasting population. This composition minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This composition follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a composition. <IMAGE>
|